Navigation Links
Arthritic Drug Approved For Use In Children With Crohn’s Diseas

The Food and Drug Administration in the U.S. have given an approval for the drug Remicade for use in children with active Crohn's disease (CD), which is a chronic// and debilitating condition.

Crohn's disease is an inflammation of the gastrointestinal tract that causes diarrhea, fever, abdominal pain, weight loss and, in some times, delayed development and stunted growth. Though it can involve any area of the gastrointestinal tract from the mouth to the anus, it commonly affects the small intestine.

Remicade has already been approved for treating rheumatoid arthritis and other conditions but now the drug will carry an additional warning about the small risk of an often-fatal lymphoma. It has been found that Remicade and other TNF blockers, may increase the risk of lymphoma or other cancers, and is not recommended for people with heart failure. There are also reports on the drug as it could cause serious infections, including tuberculosis (TB), sepsis and pneumonia, liver injury, and blood disorders.

According to drug company Johnson & Johnson the drug is the first and only biologic therapy that has been approved for the treatment of pediatric Crohn's disease. The officials said that the drug helps in reducing the signs and symptoms of the disease and helps to maintain remission in children suffering from moderate or severe form of Crohn’s disease, and those who have not responded to regular treatment.

The approval was passed after a data from a clinical trial of 112 patients aged 6 to 17 years, found that the children with moderate to severe active Crohn's disease after 10 weeks of therapy with Remicade responded well and more than half were in remission at the end of one year.

Approximately 100,000 children under the age of 17 suffer from inflammatory bowel diseases (IBD), which include CD and ulcerative colitis (UC). Remicade, known generically as infliximab, belongs to a class of drugs that suppress tumo r necrosis factor-alpha, a protein involved in inflammation.
'"/>




Related medicine news :

1. Do Arthritics Perceive the Importance of Exercise in the Management of Disease?
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
10. Pfizer’s Eraxis Approved By The FD
11. Inhalers for Kids Was Approved By the FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , ... March 24, 2017 , ... ... which will spark a conversation on the current obstacles facing infection prevention and ... completely preventable deaths caused by these infections. , The print component of ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... According to ... score is invalid because it does not obey the rules Congress has directed the ... equivalent jobs, which the GOP reform would restore. Yet, it estimates a reduction in ...
(Date:3/24/2017)... Arizona (PRWEB) , ... March 24, 2017 , ... ... Healing Center, Sedona, Arizona’s Premier Center for Shamanic Healing and Spiritual Awakening, ... Luis Delgado, June 9--24, 2017. This sacred and spiritual journey during the ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
(Date:3/24/2017)... Texas (PRWEB) , ... March 24, 2017 , ... ... 2017 the year of enhancements, upgrading their training and leads programs. , In ... University. Reserved for elite sales agents, Performance Partners is designed to teach how ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... 24, 2017 Research and Markets has ... 2017-2027" report to their offering. ... The Cell Therapy Manufacturing Market, ... market of cell therapy manufacturing and focuses both on contract ... therapies are anticipated to emerge as viable alternatives to conventional ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... ... Research, a leading publisher of cannabis market research, the legal ... 27 percent CAGR through 2021, despite conflicting signals from the ... Analytics, points out that the two biggest drivers of growth ...
Breaking Medicine Technology: